Valeo Pharma Inc., a Canadian pharmaceutical company, is proud to announce another major milestone for its two innovative Asthma therapies; Enerzair Breezehaler and Atectura Breezhaler, which have been accepted for reimbursement by the Ontario Drug Benefit program, the Manitoba Pharmacare Program, the New Brunswick Drug plan, and the NIHB and VAC federal programs.
February 24, 2022
· 4 min read